BLCO

BLCO

USD

Bausch + Lomb Corporation Common Shares

$11.500-0.150 (-1.288%)

实时价格

Healthcare
Medical Instruments & Supplies
加拿大

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$11.650

最高价

$12.050

最低价

$11.400

成交量

0.27M

公司基本面

市值

4.1B

所属行业

Medical Instruments & Supplies

国家/地区

Canada

交易统计

平均成交量

0.84M

交易所

NYQ

货币

USD

52周价格范围

最低价 $10.45当前价 $11.500最高价 $21.69

AI分析报告

最后更新: 2025年4月29日
由AI生成数据来源: Yahoo Finance, Bloomberg, SEC

BLCO (Bausch + Lomb Corporation Common Shares): What's Happening and What to Watch

Stock Symbol: BLCO Generate Date: 2025-04-29 04:57:48

Let's break down what's been going on with Bausch + Lomb stock lately, looking at the news, how the price has moved, and what some of the automated tools are predicting.

Recent News Buzz

Recent headlines about Bausch + Lomb give us a bit of a mixed picture.

First off, an analyst over at Needham decided to stick with their "Hold" rating on the stock just a few days ago. Basically, they're saying they don't see a strong reason to either buy a lot more or sell what you have right now. It's a neutral stance.

Then there was some news about the company's recycling programs for contact lenses and eye care stuff. Collecting over 100 million units sounds like a positive step for their environmental efforts. This kind of news is good for the company's image, though it doesn't usually send the stock price soaring on its own.

A little earlier in April, RBC Capital kept their "Outperform" rating, which sounds good, right? It means they think the stock should do better than the overall market. But, they also nudged their price target down a dollar, from $18 to $17. So, while they still like the stock relatively speaking, they see its potential peak a little lower than before. That's a slightly cautious note mixed into a positive rating.

Putting the news together, it feels a bit neutral to cautiously optimistic. There's nothing dramatically bad, but the lowered price target from one firm adds a note of caution despite the positive recycling story and a neutral hold rating elsewhere.

Checking the Price Chart

Looking at the stock's journey over the past few months, things got pretty interesting. Back in January and February, the price was mostly hanging out in the $16 to $18 range. Then, around late March and early April, the stock took a pretty sharp dive. It fell significantly, even dipping down towards its 52-week low of $10.46 around April 9th. That was a rough patch, and you can see the trading volume spiked during that drop, meaning a lot of shares changed hands.

Since hitting those lows in early April, though, the stock has started climbing back up. It's been on a nice recovery trend through April, getting back into the $13 to $14 area. The last recorded price was around $13.66. So, while it's still way off its highs from earlier in the year, it's shown some decent upward momentum recently after that big dip.

What the AI Thinks

An AI model looking at the stock predicts a positive move for today. It's forecasting a gain of just over 2%. Looking ahead a couple more days, the predictions are pretty flat, showing very small changes, slightly down one day and slightly up the next.

So, the AI sees some immediate potential for a bump, fitting with the recent upward trend we've seen in April.

Putting It All Together & What to Watch For

Okay, let's try to make sense of this. We've got news that's a bit mixed but not terrible, a stock price that took a big hit but is now showing signs of life with a recent recovery, and an AI predicting a short-term upward nudge.

Based on the recent price action and the AI's immediate forecast, the near-term picture might lean slightly positive, suggesting the recent momentum could continue for a bit. The stock bounced hard off its lows, and that kind of move often catches attention.

If someone were considering this stock for a potential short-term trade, the current price area, maybe around the $13.60 to $13.70 mark, could be looked at as a potential entry point. This level is right where the stock closed last and aligns with some technical ideas about support after the recent bounce.

For managing risk, a potential stop-loss level could be considered somewhere below recent significant lows or a key support area, perhaps around $12.36 as suggested by some analysis. This is about limiting potential losses if the recent recovery doesn't hold up.

On the flip side, if the stock continues its upward climb, a potential target for taking profits might be around $14.65. This level could represent a point where the upward move might pause or face resistance.

It's really important to remember the mixed signals here, though. While the technical picture and AI prediction look somewhat favorable for the very short term, the underlying company fundamentals (like lower growth, low return on equity, and higher debt) aren't screaming "buy." Plus, that lowered price target from RBC is a reminder that analysts see limits to the upside right now.

Quick Company Note

Just to keep in mind, Bausch + Lomb is a big player in eye health – think contact lenses, eye drops, surgical gear. It's part of the healthcare sector, which is often seen as more stable than some others. But, as the fundamental data hints, even in a stable sector, individual companies can have their own challenges, like managing debt or boosting growth.


Disclaimer: This analysis is for informational purposes only and is based solely on the provided data. It is not financial advice. Investing in stocks involves risk, and you could lose money. Always do your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

相关新闻

Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Bausch & Lomb, Lowers Price Target to $15

HC Wainwright & Co. analyst Yi Chen maintains Bausch & Lomb with a Buy and lowers the price target from $20 to $15.

查看更多
HC Wainwright & Co. Maintains Buy on Bausch & Lomb, Lowers Price Target to $15
Analyst Upgrades

Citigroup Maintains Neutral on Bausch & Lomb, Lowers Price Target to $13

Citigroup analyst Joanne Wuensch maintains Bausch & Lomb with a Neutral and lowers the price target from $14 to $13.

查看更多
Citigroup Maintains Neutral on Bausch & Lomb, Lowers Price Target to $13
Analyst Upgrades

Wells Fargo Maintains Equal-Weight on Bausch & Lomb, Lowers Price Target to $12

Wells Fargo analyst Larry Biegelsen maintains Bausch & Lomb with a Equal-Weight and lowers the price target from $15 to $12.

查看更多
Wells Fargo Maintains Equal-Weight on Bausch & Lomb, Lowers Price Target to $12
Analyst Upgrades

Evercore ISI Group Maintains Outperform on Bausch & Lomb, Lowers Price Target to $15.5

Evercore ISI Group analyst Vijay Kumar maintains Bausch & Lomb with a Outperform and lowers the price target from $19 to $15.5.

查看更多
Evercore ISI Group Maintains Outperform on Bausch & Lomb, Lowers Price Target to $15.5
Analyst Upgrades

Needham Reiterates Hold on Bausch & Lombto Hold

Needham analyst David Saxon reiterates Bausch & Lomb from Hold to Hold.

查看更多
Needham Reiterates Hold on Bausch & Lombto Hold
BusinessWire

Bausch + Lomb Reports More Than 100 Million Units of Contacts Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs

Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its exclusive ONE by ONE Recycling and Biotrue Eye Care Recycling

AI预测Beta

AI建议

看涨

更新于: 2025年5月3日 11:04

看跌中性看涨

59.4% 置信度

风险与交易

风险等级3/5
中风险
适合于
价值
交易指南

入场点

$11.47

止盈点

$12.49

止损点

$10.35

关键因素

DMI显示看跌趋势(ADX:21.3,+DI:15.2,-DI:19.7),表明需谨慎
交易量是平均值的13.8倍(10,957),表明极强的买入压力
MACD -0.0618低于信号线-0.0601,表明看跌交叉

保持更新

设置价格提醒,获取AI分析更新和实时市场新闻。